StockNews.AI
NAGE
StockNews.AI
104 days

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

1. NAGE reported $30.5 million in Q1 2025 sales, a 38% increase. 2. Gross margin improved to 63.4%, indicating strong profitability.

Earnings
+9.35%Current Return
VS
+0.66%S&P 500
$8.4505/07 04:10 PM EDTEvent Start
$9.2405/08 10:54 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The substantial increase in sales and gross margin reflects robust business performance, similar to previous quarterly uptrends that positively influenced stock prices.

How important is it?

The financial results showcase significant growth, likely attracting investor interest and potentially driving stock price increases.

Why Short Term?

Immediate positive sales figures are likely to boost investor confidence and stock performance quickly, similar to trends seen post-earnings announcements.

Related Companies

TRUAMGNABT
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%, up 270 basis poin.

Related News